Interplay between Ret and Fap-1 regulates CD95-mediated apoptosis in medullary thyroid cancer cells

Biochemical Pharmacology

Volumn 82, Issue 7, 2011, Pages 778-788

  Nicolini, Valentina ^a   Cassinelli, Giuliana ^a   Cuccuru, Giuditta ^a,c   Bongarzone, Italia ^b   Petrangolini, Giovanna ^a,d   Tortoreto, Monica ^a   Mondellini, Piera ^b   Casalini, Patrizia ^b   Favini, Enrica ^a   Zaffaroni, Nadia ^a   Zunino, Franco ^a   Lanzi, Cinzia ^a  

^a IRCCS   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

^d INDENA S P A   (Italy)

Author keywords

Caspase 8; CD95; Fap 1; Medullary thyroid cancer; MEN2B; RET oncogene

Indexed keywords

CASPASE 8; CELL PROTEIN; DEATH RECEPTOR; FAS ANTIGEN; INDOLE DERIVATIVE; PROCASPASE 8; PROTEIN FAP 1; PROTEIN RET; RP 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL MEMBRANE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG INHIBITION; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; MOLECULAR INTERACTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; THYROID CANCER; UPREGULATION;

ANIMALS; ANTIGENS, CD95; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, MEDULLARY; CASPASE 8; CELL LINE, TUMOR; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION REGULATION; HUMANS; INDOLES; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; NIH 3T3 CELLS; PHOSPHORYLATION; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 13; PROTO-ONCOGENE PROTEINS C-RET; THYROID NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS; TUMOR BURDEN;

EID: 80051783194     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2011.06.037     Document Type: Article

References (56)

1. R.A. Hubner, and R.S. Houlston Molecular advances in medullary thyroid cancer diagnostics Clin Chim Acta 370 2006 2 8 (Pubitemid 44096946)
2. M.B. Lodish, and C.A. Stratakis RET oncogene in MEN2, MEN2B, MTC and other forms of thyroid cancer Expert Rev Anticancer Ther 8 2008 625 632 (Pubitemid 351818356)
3. M. Cakir, and A.B. Grossman Medullary thyroid cancer: molecular biology and novel molecular therapies Neuroendocrinology 90 2009 323 348
4. M.N. Nikiforova, and Y.E. Nikiforov Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis Exp Rev Mol Diagn 8 2008 83 95
5. M. Drosten, and Putzer BM Mechanisms of disease: cancer targeting and the impact of oncogenic RET for medullary thyroid carcinoma therapy Nature Clin Pract 3 2006 564 574 (Pubitemid 44781726)
6. M. Santoro, F. Carlomagno, A. Romano, D.P. Bottaro, N.A. Dathan, and M. Grieco Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B Science 267 1995 381 383
7. F. Raue, and K. Frank-Raue Update multiple endocrine neoplasia type 2 Fam Cancer 9 2010 449 457
8. X. Liu, Q.C. Vega, R.A. Decker, A. Pandey, C.A. Worby, and J.E. Dixon receptors display different autophosphorylation sites and substrate binding specificities J Biol Chem 271 1996 5309 5312 (Pubitemid 26083860)
9. T.S. Gujral, V.K. Singh, Z. Jia, and L.M. Mulligan Molecular mechanisms of RET receptor-mediated oncogenesis in multiple endocrine neoplasia 2B Cancer Res 66 2006 10741 10749 (Pubitemid 44876969)
10. Y. Kodama, N. Asai, K. Kawai, M. Jijiwa, Y. Murakumo, and M. Ichihara The RET proto-oncogene: a molecular therapeutic target in thyroid cancer Cancer Sci 96 2005 143 148 (Pubitemid 40575914)
11. C. Lanzi, G. Cassinelli, V. Nicolini, and F. Zunino Targeting RET for thyroid cancer therapy Biochem Pharmacol 77 2009 297 309
12. C. Lanzi, G. Cassinelli, T. Pensa, M. Cassinis, R.A. Gambetta, and M.G. Borrello Inhibition of transforming activity of the ret/ptc1 oncoprotein by a 2-indolinone derivative Int J Cancer 85 2000 384 390 (Pubitemid 30030413)
13. C. Lanzi, G. Cassinelli, G. Cuccuru, N. Zaffaroni, S. Supino, and S. Vignati Inactivation of Ret/Ptc1 oncoprotein and inhibition of papillary thyroid carcinoma cell proliferation by indolinone RPI-1 Cell Mol Life Sci 60 2003 1449 1459 (Pubitemid 36900526)
14. G. Cuccuru, C. Lanzi, G. Cassinelli, G. Pratesi, M. Tortoreto, and G. Petrangolini Cellular effects and antitumor activity of RET inhibitor RPI-1 on MEN2A-associated medullary thyroid carcinoma J Natl Cancer Inst 96 2004 1006 1014 (Pubitemid 39162643)
15. G. Petrangolini, G. Cuccuru, C. Lanzi, M. Tortoreto, S. Belluco, and G. Pratesi Apoptotic cell death induction and angiogenesis inhibition in large established medullary thyroid carcinoma xenografts by Ret inhibitor RPI-1 Biochem Pharmacol 72 2006 405 414 (Pubitemid 44061744)
16. S.I. Sherman Targeted therapy of thyroid cancer Biochem Pharmacol 80 2010 592 601
17. M.-C. Bordeaxu, C. Forcet, L. Granger, V. Corset, C. Bidaud, and M. Billaud The RET proto-oncogene induces apoptosis: a novel mechanism for Hirschsprung disease EMBO J 19 2000 4056 4063 (Pubitemid 30608544)
18. P. Mehlen, and C. Thibert Dependence receptors: between life and death Cell Mol Life Sci 61 2004 1854 1866 (Pubitemid 39099295)
19. M. Drosten, G. Hilken, M. Bockmann, F. Rödicker, N. Mise, and A.N. Cranston Role of MEN2A-derived RET in maintenance and proliferation of medullary thyroid carcinoma J Natl Cancer Inst 96 2004 1231 1239 (Pubitemid 39232714)
20. K. Koga, Y. Hattori, M. Komori, R. Narishima, M. Yamasaki, and M. Hakoshima Combination of RET siRNA and irinotecan inhibited the growth of medullary thyroid carcinoma TT cells and xenografts via apoptosis Cancer Sci 101 2010 941 947
21. L. Gorla, P. Mondellini, G. Cuccuru, F. Miccich, G. Cassinelli, and M. Cremona Proteomics study of medullary thyroid carcinomas ex pressing RET germ-line mutations: identification of new signaling elements Mol Carcinog 48 2009 220 231
22. O.D. Abaan, A. Levenson, O. Khan, P.A. Furth, A. Uren, and J.A. Toretsky PTPL1 is a direct transcriptional target of EWS-FLI1 and modulates Ewing's sarcoma tumorigenesis Oncogene 24 2005 2715 2722 (Pubitemid 40593099)
23. G. Freiss, and D. Chalbos PTPN13/PTPL1: an important regulator of tumor aggressiveness Anti-Cancer Agents Med Chem 11 2011 78 88
24. G. Gloire, E. Charlier, and J. Piette Regulation of CD95/APO-1/Fas- induced apoptosis by protein phosphatases Biochem Pharmacol 76 2008 1451 1458
25. L.D. Cooley, F.F.B. Elder, A. Knuth, and R.F. Gagel Cytogenetic characterization of three human and three rat medullary thyroid carcinoma cell lines Cancer Genet Cytogenet 80 1995 138 149
26. I. Bongarzone, N. Monzini, M.G. Borrello, C. Carcano, G. Ferraresi, and E. Arighi Molecular characterization of a thyroid tumor-specific transforming sequence formed by the fusion of ret tyrosine kinase and the regulatory subunit RI alpha of cyclic AMP-dependent protein kinase A Mol Cell Biol 13 1993 358 366 (Pubitemid 23006913)
27. L. Gorla, M. Cant, F. Miccich, C. Patelli, P. Mondellini, and M.A. Pierotti RET oncoproteins induce tyrosine phosphorylation changes of proteins involved in RNA metabolism Cell Signal 18 2006 2272 2282 (Pubitemid 44636167)
28. A. Cranston, C. Carniti, S. Martin, P. Mondellini, Y. Hooks, and J. Leyland A novel activating mutation in the RET tyrosine kinase domain mediates neoplastic transformation Mol Endocrinol 20 2006 1633 1643 (Pubitemid 43967570)
29. D.H. Kern, C.R. Morgan, and S.U. Hildebrand-Zanki In vitro pharmacodynamics of 1-β-d-arabinofuranosylcytosine: synergy of antitumor activity with cis-diamminedichloroplatinum (II) Cancer Res 48 1988 117 121 (Pubitemid 18030339)
30. M. Bagnoli, E. Balladore, E. Luison, P. Alberti, F. Raspagliesi, and B. Marcomini Sensitization of p53-mutated epithelial ovarian cancer to CD95-mediated apoptosis is synergistically induced by cisplatin pretreatment Mol Cancer Ther 6 2007 762 772 (Pubitemid 46332477)
31. P. Workman, P. Twentyman, F. Balkwill, D. Chaplin, J. Double, and D. Newell United Kingdom Co-ordinating committee on Cancer Research (UKCCCR) guidelines for the welfare of animals in experimental neoplasia (second edition) Br J Cancer 77 1998 1 10 (Pubitemid 28029765)
32. F. Mollinedo, and C. Gajate Fas/CD95 death receptor and lipid rafts: new targets for apoptosis-directed cancer therapy Drug Res Updates 9 2006 51 73 (Pubitemid 43928806)
33. S. Schutze, V. Tchikov, and W. Schneider-Brachert Regulation of TNFR1 and CD95 signalling by receptor compartmentalization Nat Rev 9 2008 655 662 (Pubitemid 352032925)
34. A. Eramo, M. Sargiacomo, L. Ricci-Vitiani, M. Todaro, G. Stassi, and C.G. Messina CD95 death-inducing signaling complex formation and internalization occur in lipid rafts of type I and type II cells Eur J Immunol 34 2004 1930 1940 (Pubitemid 39256074)
35. D. Mahalingam, E. Szegezdi, M. Keane, S. de Jong, and A. Samali TRAIL receptor signalling and modulation: are we on the right TRAIL? Cancer Treat Rev 35 2009 280 288
36. V.N. Ivanov, Z. Ronai, and T.K. Hei Opposite roles of FAP-1 and dynamin in the regulation of Fas (CD95) translocation to the cell surface and susceptibility to Fas ligand-mediated apoptosis J Biol Chem 281 2006 1840 1852
37. E.T. Lam, M.D. Ringel, R.T. Kloos, T.W. Piror, M.V. Knopp, and J. Liang Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer J Clin Oncol 28 2010 2323 2330
38. I. Plaza-Menacho, L. Mologni, E. Sala, C. Gambacorti-Passerini, A.I. Magee, and T.P. Links Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting J Biol Chemistry 282 2007 29230 29240 (Pubitemid 350043334)
39. S. Cursi, A. Rufini, V. Stagni, I. Cond, V. Matafora, and A. Bachi Src kinase phosphorylates Caspase-8 on Tyr380: a novel mechanism of apoptosis suppression EMBO J 25 2006 1895 1905
40. S. Fulda Caspase-8 in cancer biology and therapy Cancer Lett 28 2009 128 133
41. S. Schenone, C. Brullo, F. Musumeci, and M. Botta Novel dual Src/Abl inhibitors for hematologic and solid malignancies Expert Opin Ivestig Drugs 19 2010 931 945
42. O.D. Abaan, and J.A. Toretsky PTPL1: a large phosphatase with a split personality Cancer Met Rev 27 2008 205 214
43. A.S. Fanning, and J.M. Anderson Protein-protein interactions: PDZ domain networks Curr Biol 11 1996 1385 1388 (Pubitemid 27012231)
44. A. Ostman, C. Hellberg, and F.D. Bohmer Protein-tyrosine phosphatases and cancer Nat Rev 6 2006 307 320
45. R. Schickel, S.M. Park, A.E. Murmann, and M.E. Peter mir-200c regulates induction of apoptosis through CD95 by targeting FAP-1 Mol Cell 38 2010 908 915
46. A. Myc, P.L. Arscott, J.D. Bretz, N.W. Thomson, and J.R. Baker Characterization of FAP-1 expression and function in thyroid follicular cells Endocrinology 140 1999 5431 5434
47. M. Kurokawa, and S. Kornbluth Caspases and kinases in a death grip Cell 138 2009 838 854
48. A.G. Porter, and S. Dhakshinamoorthy Apoptosis initiated by dependence receptors: a new paradigm for cell death? BioEssays 26 2004 656 664 (Pubitemid 38758343)
49. NTR and their effect on NF-κB activation FEBS Lett 460 1999 191 198 (Pubitemid 29495938)
50. D.E. Bredesen, P. Mehlen, and S. Rabizadeh Apoptosis and dependence receptors: a molecular basis for cellular addiction Physiol Rev 84 2004 411 430 (Pubitemid 38365489)
51. D.G. Stupack, X.S. Puente, S. Boutsaboualoy, C.M. Storgard, and D.A. Cheresh Apoptosis of adherent cells by recruitment of caspase-8 to unligated integrins J Cell Biol 155 2001 459 470 (Pubitemid 34289336)
52. C.S. Mitsiades, V. Poulaki, G. Fanourakis, E. Sozopoulos, D. McMillin, and Z. Wen Fas signaling in thyroid carcinomas is diverted from apoptosis to proliferation Clin Cancer Res 12 2006 3705 3712 (Pubitemid 44000250)
53. B. Chaigne-Delalande, J.-F. Moreau, and P. Legembre Rewinding the DISC Arch Immunol Ther Exp 56 2008 9 14
54. N.S. Wilson, V. Dixit, and A. Ashkenazi Death receptor signal transducers: nodes of coordination in immune signalling networks Nat Immunol 10 2009 348 355
55. F.H. Igney, and P.H. Krammer Death and anti-death: tumor resistance to apoptosis Nat Rev Cancer 2 2002 277 288 (Pubitemid 37328781)
56. M.A. Lemmon, and J.S. Schlessinger Cell signaling by receptor tyrosine kinases Cell 141 2010 1117 1134